Exelixis, Inc. (NASDAQ:EXEL) ranks among the most undervalued NASDAQ stocks to buy now. On September 17, Barclays began coverage of Exelixis, Inc. (NASDAQ:EXEL), rating it Equalweight and setting a ...

Merck has raised its dividend for 14 consecutive years and at an average pace of nearly 7% over the last five years. The ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Exelixis received a Hold rating and a $40.00 price target from Barclays analyst Etzer Darout on September 16. The company’s shares closed yesterday at $40.45. Take advantage of TipRanks Premium at 50% ...

Background: Determining optimal timing for intensifying the frequency of physician encounters for type 2 diabetes mellitus (T2DM) requires trade-offs between timely care and clinician burden. We aimed ...

Currently, the analyst consensus on Exelixis is a Moderate Buy with an average price target of $45.06, a 15.13% upside from current levels. In a report released today, Morgan Stanley also maintained a ...